DKSH Malaysia has expanded its partnership with Kowa Company, Ltd. to distribute Parmodia®, the newly launched triglycerides (TG) lowering drug. This collaboration represents a shared dedication to innovation, growth, and providing medical products in Malaysia.
Petaling Jaya, Malaysia, January 24, 2025 – DKSH Business Unit Healthcare, a strategic partner for companies seeking to grow their healthcare business in Asia and beyond, is proud to announce the expansion of its partnership with Kowa Company, Ltd., a global enterprise with various business fields including the manufacturing and sales of medicines to Malaysia.
Under the extended agreement, DKSH Malaysia Healthcare will undertake the responsibility for providing comprehensive Market Expansion Services, including marketing and sales, for the newly launched triglycerides lowering drug, Parmodia® film-coated tablets 0.1mg (MAL23056003AZ).
Since 2022, DKSH Malaysia Healthcare has been distributing a range of Kowa products, Parmodia®, introduced in Malaysia in February 2024, marks the latest addition to Kowa’s product lineup and repre-sents a new class of medications known as selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα).
Parmodia® is indicated as an adjunctive therapy to diet or other nonpharmacological treatment such as exercise to reduce TG and to increase high density lipoprotein-cholesterol (HDL-C) in patients with dyslipidemia characterized by a high level of TG ≥150 mg/dL, particularly when there is evidence of associated risk such as hypertension and smoking.
Sandeep Tewari, Head Country Leadership and Vice President, Healthcare, DKSH Malaysia, added: “We eagerly anticipate the evolution of our collaboration with Kowa. This partnership symbolizes a joint commitment to innovation, growth, and delivering exceptional medical products to the Malaysian patients, underscoring our commitment to enriching people’s lives and providing healthcare for all.”
About Kowa Company, Ltd.
Since its founding in 1894 as a cotton fabric wholesaler in Japan, Kowa Group has grown into a global enterprise with about 130-years of history. As the core of the group, Kowa Company, Ltd. is actively engaged in various business fields including pharmaceutical R&D, the trading of textiles, machinery, and construction materials, in addition to the manufacturing and sales of medicines, medical devices, vision units, energy saving and energy creating products.
www.kowa.co.jp/eng/
About DKSH
DKSH’s purpose is to enrich people’s lives. For almost 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 29,040 specialists, generating net sales of CHF 11.1 billion in 2023. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, and over-the-counter products as well as medical devices. With around 8,140 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2023.
www.dksh.com/hec